moatshark My

All holdings

Edwards Lifesciences

EW

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
1
In their latest 13F (Q3 2026)
See who
Value held
$14.9m
Combined value at quarter end
Last quarter
0 bought
1 sold or trimmed
Price at Q2 ’26 end
$90.46
+13.0% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

-16.1%Q3 ’24
+11.7%Q4 ’24
+3.7%Q1 ’25
+4.4%Q2 ’25
-2.9%Q3 ’25
+9.6%Q4 ’25
-6.1%Q1 ’26
+13.0%Q2 ’26
Q3 ’24: -16.1%; Q4 ’24: +11.7%; Q1 ’25: +3.7%; Q2 ’25: +4.4%; Q3 ’25: -2.9%; Q4 ’25: +9.6%; Q1 ’26: -6.1%; Q2 ’26: +13.0%

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

2Q4 ’23
2Q1 ’24
2Q2 ’24
2Q3 ’24
2Q4 ’24
1Q1 ’25
1Q2 ’25
1Q3 ’25
1Q4 ’25
1Q1 ’26
1Q2 ’26
0Q3 ’26
Q4 ’23: 2; Q1 ’24: 2; Q2 ’24: 2; Q3 ’24: 2; Q4 ’24: 2; Q1 ’25: 1; Q2 ’25: 1; Q3 ’25: 1; Q4 ’25: 1; Q1 ’26: 1; Q2 ’26: 1; Q3 ’26: 0

Counts the managers on this site whose 13F for that quarter includes Edwards Lifesciences.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Edwards Lifesciences
Wedgewood Partners3.1%$14.9m$14.9mTrimmed -3.4%12 qtrs

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works
From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Insider purchases and sales of Edwards Lifesciences
Bought or soldFiling
8 Oct 2026Lippis Daniel J.CVP, TAVR▼ Sold619$85.65$53kForm 4
11 Sep 2026Lippis Daniel J.CVP, TAVR▼ Sold619$87.51$54kForm 4
31 Aug 2026Dahl Andrew M.SVP, Corporate Controller▼ Sold544$91.06$50kForm 4
28 Aug 2026Bruls AnnetteCVP, EMEACLA▼ Sold2,644$89.98$238kForm 4
26 Aug 2026Chopra DaveenCVP, TMTT, Surgical & IHFM▼ Sold30,646$90.99$2.8mForm 4
26 Aug 2026Markowitz WayneCVP, JAPAC▼ Sold1,240$91.47$113kForm 4
26 Aug 2026Chopra DaveenCVP, TMTT, Surgical & IHFM▼ Sold1,154$91.76$106kForm 4
11 Aug 2026Lippis Daniel J.CVP, TAVR▼ Sold619$92.03$57kForm 4
30 Jul 2026Markowitz WayneCVP, JAPAC▼ Sold146.313$86.03$13kForm 4
28 Jul 2026Markowitz WayneCVP, JAPAC▼ Sold9,628$85.06$819kForm 4
27 Jul 2026Zovighian Bernard JCEO▼ Sold2,920.551$83.93$245kForm 4

About the company

Sector
Health care · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Incorporated in
Delaware
Financial year ends
31 December
Shares outstanding
576m at 31 Jul 2026
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

$2.0bn2013
$2.5bn2015
$3.4bn2017
$4.3bn2019
$5.2bn2021
$5.0bn2023
$6.1bn2025
2013: $2.0bn; 2014: $2.3bn; 2015: $2.5bn; 2016: $3.0bn; 2017: $3.4bn; 2018: $3.7bn; 2019: $4.3bn; 2020: $4.4bn; 2021: $5.2bn; 2022: $4.5bn; 2023: $5.0bn; 2024: $5.4bn; 2025: $6.1bn
Edwards Lifesciences revenue and net income by year
YearRevenueNet income
2025$6.1bn$1.1bn
2024$5.4bn$4.2bn
2023$5.0bn$1.4bn
2022$4.5bn$1.5bn
2021$5.2bn$1.5bn
2020$4.4bn–
2019$4.3bn–
2018$3.7bn–
2017$3.4bn–
2016$3.0bn–
2015$2.5bn–
2014$2.3bn–
2013$2.0bn–

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.